Considering the complexity and high cost of large-scale instruments, here we mainly summarize the application and advance of enhanced fluorescence-sensing platforms in the detection of AD biomarkers in blood, including Aβ, tau, metal ions and microRNA. This evidence concerns the gene MAPT and Alzheimer disease.